Introduction {#s1}
============

Since the mid-1970s, the widespread use of 4-hydroxycoumarin instead of short-acting rodenticides (e.g., arsenic and strychnine) has increased the incidence of long-acting anticoagulant rodenticides (LAARs) poisoning ([@B1]). Currently, the majority of commercially available LAARs are second-generation 4-hydroxycoumarin such as brodifacoum and bromadiolone that have increased activity and a longer duration of action than those of the parent compound ([@B2], [@B3]). Thus, they are also referred to as "superwarfarins." 4-Hydroxycoumarin inhibits the activity of hepatic vitamin K1 epoxide reductase, which is involved in the synthesis of the active form of vitamin K, and subsequently vitamin K-dependent blood clotting factors II, VII, IX, and X ([@B4]). The mean half-life of factors II, VII, IX, and X is 41.0, 6.2, 13.9, and 16.5 h, respectively ([@B5]). Therefore, after ingestion of 4-hydroxycoumarin, coagulopathy may be delayed by several hours to days until the preformed vitamin K and active clotting factors are exhausted.

Clinical manifestations of 4-hydroxycoumarin poisoning are characterized by prolonged multiple-site hemorrhage, and may range from no symptom to life-threatening bleeding, which is mainly determined by the ingested dose of the active ingredient. Significant coagulopathy usually results from the ingestion of large amounts of this active ingredient without timely diagnosis and treatment. And clinically important manifestation would not be observed in children who ingested less than 1 box of superwarfarin ([@B6]). However, in contrast to that in adults, the ingested dose of rodenticides in children is very difficult to be determined because of the uncertainties in the exposure history ([@B7]). Preschool children who comprise the largest at-risk population of rodenticide poisoning are usually unable to accurately describe the poisoning details including ingested doses. Suicidal adolescents, for various reasons, may intentionally conceal the facts. Meanwhile, some guardians do not witness the process of rodenticide ingestion. Furthermore, 4-hydroxycoumarin is usually unnoticed because it is flavorless ([@B8]). Some consumers use the concentrates to prepare bait in a manner not strictly in accordance with the instructions and, therefore, the amount of the active substance ingested is unknown.

These domestic and household challenges make it extremely difficult to estimate the ingested dose accurately. When the ingested dose is known, decontamination and treatment can increase the elimination of toxins resulting in the decrease of toxic *in vivo* dose, and vitamin K administration will decrease the toxic effects. As a result, toxic dose is not always consistent with ingested dose. To date, there are very little data available on the toxic dose estimation of 4-hydroxycoumarin in humans. Therefore, the following study was conducted to establish an evaluation system for toxic doses in pediatric patients with 4-hydroxycoumarin rodenticide intoxication. Using this evaluation system, we aimed to guide the accurate administration of poisoned patients.

Material and methods {#s2}
====================

Study design
------------

A Delphi group consisted of 12 pediatric experts and 8 toxicologists were established to aid with item selection and gradation. A systematic review of the literature was performed using the following search items: "4-hydroxycoumarin," "coumarins," "anticoagulant," "long-acting anticoagulant," "anticoagulant rodenticide," "superwarfarin," "brodifacoum," and "bromadiolone." Databases queried included PubMed, Science Citation Index, and OVID. 10 items (age, amount ingested, reason, LAARs type, coagulation function, severity of bleeding, time from ingestion to first-time gastric lavage, time from ingestion to first-time plasmapheresis, time from ingestion to hospitalization, and frequency of plasmapheresis) which closely related to toxic dose and severity of disease were initially drafted through review of the literature. The Delphi group members ranked each item from 0(not important) to 4(extremely important) separately. The responses of all Delphi members were summarized, processed, and sent back to the experts. Consensus was reached after two rounds and 7 items (amount ingested, reason, coagulation function, severity of bleeding, time from ingestion to first-time gastric lavage, time from ingestion to first-time plasmapheresis and frequency of plasmapheresis) were selected finally. Then gradations were weighted by analytic hierarchy process. Finally, the scoring system for TDCH was established according to item weighting.

Trained physicians recorded the information, and prothrombin time (PT), activated partial prothrombin time (APTT), and international normalized ratio (INR) were measured for all patients on admission, and toxic dose grades of all patients were made by the TDCH scores. All patients were routinely followed up, and PT, APTT, and INR repeated at a month. For patients who needed vitamin K1 treatment more than a month, they were further followed until recovery. The ability of TDCH score~48h~ predicting coagulopathy and TDCH score predicting prolonged administered with vitamin K~1~ was assessed with the area under the receiver operating characteristic (AUROC) analysis. In 38 patients who arrived at the hospital within 48 h, TDCH score~48h~ were obtained according to manifestations and lab findings. And prolonged administration with vitamin K~1~ was defined as longer than a month.

Patients
--------

Sixty-five children at the West China Second University Hospital of Sichuan University, who were diagnosed with 4-hydroxycoumarin rodenticide intoxication between May 2008 and September 2016, were included in the study. The diagnosis of 4-hydroxycoumarin rodenticide intoxication was based on exposure history, clinical effects, physical examination, and laboratory results. Main hemorrhagic symptoms of the enrolled patients included epistaxis, petechiae, gastro- intestinal bleeding, hematuria, ecchymoma, and gingival bleeding. In 17 cases who lacked a definitive history of ingestion, the diagnoses were confirmed using high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) detection of blood samples ([@B9]). The following were the study exclusion criteria: ([@B1]) combined ingestion of other pesticides or anticoagulants such as warfarin; ([@B2]) hereditary coagulation deficiency; and ([@B3]) history of serious underlying disease such as heart, lung, renal, or liver disease.

Statistical analysis
--------------------

The statistical package for the social sciences (SPSS) version 19.0 software was used for the statistical analyses. The measured data were expressed as the mean ± standard deviation (*SD*) and counted data were expressed as numbers and percentages in parentheses. The differences between groups were compared using the Student\'s *t*-test for continuous variables and the chi-square test for categorical variables. The Delphi method was used to select items. Analytic hierarchy process was used to determine the weight of each item. AUROC analysis was used to calculate cutoff values, sensitivity, and specificity. Differences with *p-*values \< 0.05 were considered statistically significant.

Ethics statements
-----------------

This study was performed according to the Declaration of Helsinki and was approved by the Medical Ethics Review Committee of West China Second University Hospital of Sichuan University (reference number 2017032). All parents of participants signed an informed consent form prior to enrolment.

Results {#s3}
=======

Scoring system for toxic doses in children with 4-hydroxycoumarin (TDCH)
------------------------------------------------------------------------

The specific calculation of the evaluation system is shown in Table [1](#T1){ref-type="table"}.

###### 

Scoring system for toxic dose in children with 4-hydroxycoumarin (TDCH).

  **Contributing factors**                                       **Scores**                           
  -------------------------------------------------------------- ------------------------------------ ----
  **AMOUNT INGESTED**[^a^](#TN1){ref-type="table-fn"}                                                 
  **Concentrate (mL)**                                           **Bait (g)**                         
  \<0.2                                                          \<10                                 12
  0.2--2                                                         10--30                               16
  2--5                                                           30--50                               20
  ≥5                                                             ≥50                                  24
  **REASON**[^a^](#TN1){ref-type="table-fn"} **(OPTIONAL)**                                           
  Accidental                                                                                          16
  Unknown[^b^](#TN2){ref-type="table-fn"}                                                             20
  Suicide                                                                                             24
  **LABORATORY EXAMINATIONS**                                                                         
  INR                                                            APPT                                 
  \<1.5                                                          Normal                               0
  1.5--3                                                         \>100--150% increase from baseline   2
  3--5                                                           \>150--250% increase from baseline   4
  ≥5                                                             ≥250% increase from baseline         6
  **BLEEDING**[^c^](#TN3){ref-type="table-fn"}                                                        
  No                                                                                                  0
  Mild                                                                                                2
  Moderate                                                                                            4
  Severe                                                                                              6
  **Weakening factors**                                          **Scores**                           
  **TIME FROM INGESTION TO FIRST-TIME GASTRIC LAVAGE (HOURS)**                                        
  ≥24 or no                                                                                           0
  4--24                                                                                               −2
  1--4                                                                                                −4
  \<1                                                                                                 −6
  **TIME FROM INGESTION TO FIRST-TIME PLASMAPHERESIS (DAYS)**                                         
  no                                                                                                  0
  ≥7                                                                                                  −2
  1--7                                                                                                −4
  \<1                                                                                                 −6
  **FREQUENCY OF PLASMAPHERESIS**                                                                     
  0                                                                                                   0
  1                                                                                                   −1
  2--3                                                                                                −2
  ≥4                                                                                                  −3

*The total score of toxic dose was obtained by summing up the points of contributing factors and weakening factors. High dose group: \>24 points; medium: 15--24 points; low: \< 15 points*.

*When the amount ingested was clear, the score was obtained according to amount ingested. When the amount ingested was uncertain, the score was obtained according to poisoning reason*.

*Reasons for poisoning were unknown because exposure history was unavailable*.

*No, no bleeding at all; mild, bruising, petechiae, occasional mild epistaxis with very little or no interference with daily living; moderate, more severe skin manifestations with some mucosal lesions and more troublesome epistaxis or menorrhagia; severe, bleeding episodes (epistaxis, melena, menorrhagia and/or intracranial hemorrhage) requiring hospital admission and/or blood transfusions ([@B10]). TDCH, toxic dose in children with 4-hydroxycoumarin; INR, international normalized ratio; APPT, activated partial thromboplastin time*.

Baseline characteristics
------------------------

As shown in Table [2](#T2){ref-type="table"}, 65 children with 4-hydroxycoumarin intoxication aged between 9 months and 15 years were included in the study. The pediatric 4-hydroxycoumarin poisoning cases exhibited a bimodal age distribution. Poisoning Reasons of 17 patients were unknown because their exposure history was unavailable, of whom, 9 repeatedly denied any exposure to rodenticides, and other 8 denied the ingestion despite evidence of the use of rodenticides in their household. The diagnosis of them was confirmed by LC-MS/MS method. Epistaxis (23/65) and petechiae (21/65) were main hemorrhagic symptoms, followed by gastro- intestinal bleeding (16/65), hematuria (7/65), ecchymoma (7/65) and gingival bleeding (6/65). Mortality rate was zero.

###### 

Baseline characteristics of 65 children with 4-hydroxycoumarin intoxication.

  **Variable**                              **N (%) or Mean (*SD*)**
  ----------------------------------------- --------------------------
  **AGE (YEARS)**                           
  \<6                                       44 (67.7)
  6-- \<10                                  8 (12.3)
  ≥10                                       13 (20.0)
  **SEX**                                   
  Male                                      35 (53.8)
  Female                                    30 (46.2)
  **ENVIRONMENT**                           
  Rural                                     30 (46.2)
  Urban                                     35 (53.8)
  **RODENTICIDE TYPE**                      
  Brodifacoum                               29 (44.6)
  Bromadiolone                              36 (55.4)
  Reason                                    
  Accidental                                40 (61.5)
  Suicide                                   8 (12.3)
  Unknown[^a^](#TN4){ref-type="table-fn"}   17 (26.2)
  **LABORATORY EXAMINATIONS**               
  PT (seconds)                              33.0 (36.1)
  APTT (seconds)                            83.3 (66.9)
  **BLEEDING**                              
  Yes                                       36 (55.4)
  No                                        29 (44.6)

*Data are number (%) or median (standard deviation)*.

*Reasons for poisoning were unknown because exposure history was unavailable*.

Demographics and clinical characteristics
-----------------------------------------

Selected demographics and clinical characteristics of the high, medium, and low dose groups are shown in Table [3](#T3){ref-type="table"}. There was no statistically significant difference in sex and environment (not shown in the table) among the three groups. Overall, patients in the high-dose had a wide age distribution, poisoned for various reasons, and arrived at the hospital later than 24 h (26/29, 89.7%), been misdiagnosed initially (25/29, 86.2%), not treated by gastric lavage (27/29, 93.1%), and developed severe hemorrhage. While most children in the low-dose were younger than 6 years (26/28, 92.9%), all have experienced accidental exposure, arrived at the hospital and received gastric lavage within 24 h, obtained a definite diagnosis, and be asymptomatic.

###### 

Demographics and clinical characteristics of high, medium, and low dose group.

  **Variable**                                               **High[^a^](#TN5){ref-type="table-fn"}*N* = 29**   **Medium *N* = 8**   **Low *N* = 28**   ***p-*value**
  ---------------------------------------------------------- -------------------------------------------------- -------------------- ------------------ ------------------------------------------------------------------------
  **SEX**                                                                                                                                               
  Male                                                       13 (44.8)                                          5 (62.5)             17 (60.7)          0.449
  Female                                                     16 (55.2)                                          3 (37.5)             11(39.3)           
  **AGE (YEARS)**                                                                                                                                       
  \<6                                                        15 (51.7)                                          3 (37.5)             26 (92.9)          [^d^](#TN8){ref-type="table-fn"}[^e^](#TN9){ref-type="table-fn"}\<0.05
  6 ≤ 10                                                     6 (20.7)                                           1 (12.5)             1 (3.6)            
  ≥10                                                        8 (27.6)                                           4 (50.0)             1 (3.6)            
  **REASON**                                                                                                                                            
  Accidental                                                 7 (24.1)                                           5 (62.5)             28 (100)           \<0.05
  Suicide                                                    5 (17.2)                                           3 (37.5)             0 (0)              
  Unknown[^b^](#TN6){ref-type="table-fn"}                    17 (58.6)                                          0 (0)                0 (0)              
  **TIME FROM INGESTION TO HOSPITALIZATION (HOURS; DAYS)**                                                                                              
  \<4 h                                                      2 (6.9)                                            4 (50.0)             24 (85.7)          \<0.05
  4--24 h                                                    1 (3.4)                                            2 (25.0)             4 (14.3)           
  24 h−7 d                                                   2 (6.9)                                            1 (12.5)             0 (0)              
  ≥7 d                                                       24 (82.8)                                          1 (12.5)             0 (0)              
  **TIME FROM INGESTION TO GASTRIC LAVAGE (HOURS)**                                                                                                     
  \<1                                                        0 (0)                                              0 (0)                9 (32.1)           \<0.05
  1--4                                                       2 (6.9)                                            4 (50.0)             14 (50.0)          
  4--24                                                      0 (0)                                              1 (12.5)             5 (17.9)           
  No                                                         27 (93.1)                                          3 (37.5)             0 (0)              
  **INITIAL DIAGNOSIS**                                                                                                                                 
  Definite                                                   4 (13.8)                                           6 (75.0)             28 \[100\]         \<0.05
  Misdiagnosis                                               25 (86.2)                                          2 (25.0)             0 (0)              
  **BLEEDING SITE**                                                                                                                                     
                                                             3.14 (1.43)                                        1.63 (1.41)          0.04 (0.19)        \<0.05
  **ANEMIA**                                                                                                                                            
  No                                                         5 (17.2)                                           6 (75.0)             27 (96.4)          \<0.05
  Mild                                                       5 (17.2)                                           0 (0)                1 (3.6)            
  Moderate                                                   15 (51.7)                                          2 (25.0)             0 (0)              
  Severe                                                     4 (13.8)                                           0 (0)                0 (0)              
  **LABORATORY EXAMINATIONS**                                                                                                                           
  Hb (g/L)                                                   80.8 (23.0)                                        114.5 (23.0)         123.1 (10.1)       [^c^](#TN7){ref-type="table-fn"}[^d^](#TN8){ref-type="table-fn"}\<0.05
  PT (seconds)                                               70.2 (42.2)                                        20.0 (19.9)          11.5 (1.0)         [^c^](#TN7){ref-type="table-fn"}[^d^](#TN8){ref-type="table-fn"}\<0.05
  APTT (seconds)                                             141.4 (55.7)                                       62.4 (46.2)          29.0 (5.1)         \<0.05
  INR                                                        5.4 (2.1)                                          2.6 (1.8)            1.0 (0.1)          \<0.05

*Data are number (%) or median (standard deviation)*.

*High dose group: \>24 points; medium: 15--24 points; low: \<15 points*.

*Reasons for poisoning were unknown because exposure history was unavailable*.

*p \< 0.05, the high-dose group vs. the medium-dose group*.

*p \< 0.05, the high-dose group vs. the low-dose group*.

*p \< 0.05, the medium-dose group vs. the low-dose group. PT, prothrombin time; APPT, activated partial thromboplastin time; INR, international normalized ratio*.

In the low-dose group, 24 of 28 patients usually consumed a few granules or had a "taste" of the rodenticides and did not develop coagulopathy. Although ingested large amounts (0.5--6 mL), the other four patients were also classified in the low-dose group and only one microscopic hematuria was observed. This might be because all of them were administered gastric lavage within an hour or plasmapheresis in the early phase, or both.

Reasons for poisoning
---------------------

As shown in Table [4](#T4){ref-type="table"}, accidental exposure patients were younger than 6 years (34/40, 85.0%), and have taken baits (23/40, 57.5%). In 8 intentional suicide patients, 7 cases were older than 10 years, other one was at 8 years and 9 months old, and all of them have ingested the concentrates.

###### 

Comparison of different reasons in children with 4-hydroxycoumarin intoxication.

  **Variable**                                               **Accidental *N* = 40**   **Suicide *N* = 8**   **Unknown[^a^](#TN10){ref-type="table-fn"}*N* = 17**   ***p-*value**
  ---------------------------------------------------------- ------------------------- --------------------- ------------------------------------------------------ --------------------------------------------------------------------------
  **AGE (YEARS)**                                                                                                                                                   
  \<6                                                        34 (85.0)                 0 (0)                 10 (58.8)                                              [^b^](#TN11){ref-type="table-fn"}[^d^](#TN13){ref-type="table-fn"}\<0.05
  6 ≤ 10                                                     3 (7.5)                   1 (12.5)              4 (23.5)                                               
  ≥10                                                        3 (7.5)                   7 (87.5)              3 (17.6)                                               
  **AVAILABLE FORMS**                                                                                                                                               
  Bait                                                       23 (57.5)                 0 (0)                 0 (0)                                                  \<0.05
  Concentrate                                                17 (42.5)                 8 (100)               0 (0)                                                  
  Unknown                                                    0 (0)                     0 (0)                 17 (100)                                               
  **TIME FROM INGESTION TO HOSPITALIZATION (HOURS; DAYS)**                                                                                                          
  \<4 h                                                      28 (70.0)                 2 (25.0)              0 (0)                                                  \<0.05
  4--24 h                                                    6 (15.0)                  0 (0)                 0 (0)                                                  
  24 h−7 d                                                   3 (7.5)                   1 (12.5)              0 (0)                                                  
  ≥7 d                                                       3 (7.5)                   5(62.5)               17 (100)                                               
  **TIME FROM INGESTION TO GASTRIC LAVAGE (HOURS)**                                                                                                                 
  \<1                                                        8 (20.0)                  0 (0)                 0 (0)                                                  [^b^](#TN11){ref-type="table-fn"}[^c^](#TN12){ref-type="table-fn"}\<0.05
  1--4                                                       18 (45.0)                 2 (25.0)              0 (0)                                                  
  4--24                                                      7 (17.5)                  0 (0)                 0 (0)                                                  
  No                                                         7 (17.5)                  6 (75.0)              17 (100)                                               
  **INITIAL DIAGNOSIS**                                                                                                                                             
  Definite                                                   35 (87.5)                 2 (25.0)              1 (5.9)                                                [^b^](#TN11){ref-type="table-fn"}[^c^](#TN12){ref-type="table-fn"}\<0.05
  Misdiagnosis                                               5 (12.5)                  6 (75.0)              16 (94.1)                                              

*Data are number (%) or median (standard deviation)*.

*Reasons for poisoning were unknown because exposure history was unavailable*.

*p \< 0.05, the accidental exposure group vs. the suicide group*.

*p \< 0.05, the accidental exposure group vs. the exposure history unknown group*.

*p \< 0.05, the suicide group vs. the exposure history unknown group*.

Six of eight intentional suicide patients concealed what they ingested and 17 patients had no definite history of ingestion. These patients were more likely to arrive at the hospital after 24 h (suicide 6/8 and unknown 16/17), experience higher incidence of misdiagnosis (suicide 6/8 and unknown 16/17), thus not receive gastric lavage treatment (suicide 7/8 and unknown 17/17), and eventually be divided to high (suicide 5/8 and unknown 17/17), or medium (suicide 3/8) dose group than accidental exposure were. Moreover, since the parents of 5 accidental exposure patients did not realize the risk of consuming the agent, neither did provide exposure history to physicians on admission, their kids were also misdiagnosed initially, and were divided to high (4/5) or medium (1/5) dose finally. Of 27 misdiagnosed patients, 11 were misdiagnosed once, another 11 misdiagnosed twice, 2 misdiagnosed thrice, and remaining 3 misdiagnosed more than thrice. No exposure was identified in a one-year-old boy, leading to misdiagnosis with hemophilia. And it took 1 year to make a definite diagnosis using LC-MS/MS method.

Predictability of TDCH
----------------------

Firstly, the AUROC, Youden index, sensitivity, and specificity were calculated to determine the predictability for coagulopathy of TDCH (Table [5](#T5){ref-type="table"}). Of 38 patients arrived at hospital within 48 h, patients a score~48h~ ≥ 15 had higher incidence of coagulopathy (6/8, 75.0%) than patients with a score~48h~ \< 15 (3/30, 10.0%). The AUROC, Youden index, sensitivity and specificity were 0.912, 0.727, 0.727, 1.000, respectively, which showed middle sensitivity and high specificity in predicting for coagulopathy of TDCH. 27 patients who arrived at hospital after 48 h all presented with coagulopathy when admitted. So we did not use TDCH to predict coagulopathy in these patients.

###### 

Predictability of TDCH.

                                                                  **AUROC**   **SE**   ***p* value**   **Asymptotic 95% confidence**   **Cutoff point**   **Youden index**   **Sensitivity**   **Specificity**   
  --------------------------------------------------------------- ----------- -------- --------------- ------------------------------- ------------------ ------------------ ----------------- ----------------- -------
  Coagulopathy[^a^](#TN14){ref-type="table-fn"}                   0.912       0.058    0.000           0.798                           1.000              15                 0.727             0.727             1.000
  Prolonged administered with vitamin $\text{K}_{1}^{\text{b}}$   0.995       0.005    0.000           0.985                           1.000              15                 0.933             1.000             0.933

*TDCH score~48h~ (n = 38) were predictive for coagulopathy*.

*^b^TDCH scores (n = 65) were predictive for prolonged administered with Vitamin K~1~ (≥ 1 month). AUROC, area under the receiver operating characteristic; SE, standard error*.

Secondly, the predictability for prolonged administration with vitamin K~1~ (≥ 1 month) of TDCH was analyzed by AUROC. Of all patients, 37 in the high and medium dose group with a score ≥ 15 has higher incidence (35/37, 94.6%) of prolonged administration with vitamin K~1~ (≥ 1 month) than other 28 patients with a score \< 15 (0/28, 0%). The AUROC, Youden index, sensitivity and specificity were 0.995, 0.933, 1.000, 0.933, respectively. The results above showed high predictability for prolonged administration with vitamin K~1~.

Discussion {#s4}
==========

We introduced a novel evaluation system for the determination of toxic dose in children with 4-hydroxycoumarin rodenticide intoxication. In this study, deliberate suicide patients (8/8, 100%) presented with obvious hemorrhage and were divided to high or medium dose group, while (28/40, 70%) accidental exposure patients were often asymptomatic and were divided to low dose. Our observations were consistent with an analysis of the American Association of Poison Control Centers\' National Poison Data System (NPDS) showing that intentional exposures had a greater frequency of serious outcomes than unintentional exposures did ([@B11]). In addition, we found that 17 patients whose exposure information was unavailable all presented with severe hemorrhage and were divided to high dose. Interestingly, 18 patients younger than 6 years were divided into the high or medium group in our study. They presented with coagulopathy, inconsistent with a previous study showing that preschool-aged children with unintentional acute exposure to superwarfarin rodenticides would not likely develop any significant coagulation abnormalities ([@B12]). Of the 18 patients, ten denied ingestion of rodenticides and, therefore, they were not administered with gastric lavage. Five with accidental exposures ingested large amounts of concentrations (ranging from 0.5 to 2.5 mL), and three of the five subjects were administered with gastric lavage within 4 h. The remaining three with accidental exposures ingested unclear amounts and only one of them received gastric lavage. Ingestion of large amounts and delayed treatment may be the main causes of coagulopathy in these patients.

Misdiagnosis is the most common clinical challenge of 4-hydroxycoumarin rodenticide poisoning. It mainly occurred both in intentional suicide patients (6/8, 75.0%) and those who had no definite history of ingestion (16/17, 94.1%). The key element of diagnosis, the history of ingestion, is often unavailable in these patients. As a result, misdiagnosis and delayed treatment are common, often leading to severe consequences. 4-Hydroxycoumarin rodenticide poisoning is usually misdiagnosed as hemophilia when it occurs in little children without a definite history of ingestion. Because the onset is insidious, the hemorrhage is prolonged and recurrent, and factors IX and X is decreased. Anticoagulant rodenticides poisoning should be considered in cases of unexplained multi-site bleeding and vitamin K-dependent coagulation disorder. The key to avoiding misdiagnosis is to obtain a clear history of rodenticides ingestion or have access to a toxicology screen, such as LC-MS/MS.

The TDCH could evaluate toxic doses, predict coagulopathy in the early and guide the administration of vitamin K~1~. Limited studies have shown that a child weighing 10 kg would need to acutely ingest a minimum of 0.15 mg/kg of brodifacoum for coagulopathy to develop ([@B13]). However, four of our patients ingested large amounts of rodenticides, but they did not present with obvious coagulopathy because of the timely gastric lavage and plasmapheresis. Thus, the amount ingested could not be predictive of coagulopathy. Using TDCH, we found patients with a score~48h~ ≥ 15 were in the high bleeding risk category. Early identification of these patients is crucial for not only promoting precise early treatment of high-risk patients, but also avoiding unnecessary examinations and treatments in those with low risks. For high-risk patients, vitamin K~1~ should be administered preventively as soon as possible. Up to now, there was no clear consensus on the appropriate use of vitamin K~1~ ([@B14]). According to a literature review ([@B7]), the duration of vitamin K~1~ ranged from 28 days to 730 days. And in our observation, patients with obvious coagulopathy required vitamin K~1~ at least for one month because of ongoing bleeding or coagulopathy. So we chose longer than a month as the length of vitamin K~1~ treatment. We found that patients in the high and medium dose with TDCH scores ≥ 15 required treatment with vitamin K~1~ for more than a month. With an AUROC of 0.995 and sensitivity of 0.933 and specificity of 1.000, the TDCH has high predictability.

However, this study still has some limitations. First, most diagnoses were based on the history of exposure to the rodenticides without qualitative identification of 4-hydroxycoumarin. Qualitative identification of 4-hydroxycoumarin in the blood was performed only in some patients, and none of the patients were subjected to quantitative analysis of the toxin. But this measurement is not currently widely performed even in the developed countries. Quantitative analyses, which can objectively reflect the toxic *in vivo* dose, are gold standard criteria for diagnosis. The TDCH could be further developed by using quantitative analyses. Second, the number of patients was insufficient in our study, and the TDCH score should be further verified and improved in larger, prospective studies.

Conclusion {#s5}
==========

The TDCH system is not only suitable for evaluating toxic doses on admission and predicting the risk of coagulopathy in the early stage, but also helps to appropriate treatment. Using TDCH, we found patients with a score~48h~ ≥ 15 were in the high bleeding risk category. And patients with a scores ≥ 15 required treatment with vitamin K~1~ for more than a month. It is a simple and non-invasive method, and can be widely used in all areas, especially in developing countries. We hypothesize that modified TDCH can also be applied to other intoxication in children.
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